Ibrance patent expiration?

When Does the Patent for Ibrance Expire?

According to the patent records on DrugPatentWatch.com [1], the patents for Ibrance (palbociclib), a CDK4/6 inhibitor used in the treatment of breast cancer, are set to expire in 2028.

What Does Patent Expiration Mean for Patients and Healthcare Providers?

Ibrance's patent expiration does not automatically mean the drug will become generic. The pharmaceutical company that developed Ibrance, Pfizer, will likely continue to manufacture and market the drug even after the patents expire. However, the loss of exclusivity may lead to increased competition from generic or biosimilar versions of Ibrance.

Can Biosimilars Enter the Market Before Patent Expiration?

Biosimilars, which are highly similar versions of biologic medications, may enter the market before the Ibrance patent expires. The FDA has a separate regulatory pathway for biosimilars, which can result in a faster approval process. However, Pfizer may still have some intellectual property protection, such as method-of-use patents, that can limit the entry of biosimilars into the market.

Why Are Companies Challenging the Patent for Ibrance?

Several companies, including Mylan and Sandoz, have challenged the patents for Ibrance in court, citing patent invalidity or non-infringement. These challenges may ultimately delay the entry of generic or biosimilar versions of Ibrance into the market [2].

What Happens When Exclusivity Expires?

When the exclusivity for Ibrance expires, other companies may begin to develop and market generic or biosimilar versions of the drug. This can lead to increased competition, which may result in lower prices for the medication.

References

[1] DrugPatentWatch.com. (n.d.). Palbociclib (Ibrance) Patent Expiration Dates. Retrieved from https://www.drugpatentwatch.com/patent/US-8586380

[2] Pfizer v. Mylan, 21-1150 (Fed. Cir. 2022).